#1 Clinical Trials Search in Europe

Ontasameran

This article discusses the clinical trials of Ontasameran, a component of the drug BNT111, which is being studied for the treatment of advanced melanoma. BNT111 is a novel therapy that combines four mRNA molecules, including Ontasameran, to target specific proteins associated with melanoma. The trials aim to evaluate the effectiveness and safety of BNT111 alone and in combination with another drug, cemiplimab, in patients with late-stage skin cancer that has not responded to other treatments.

Table of Contents

What is ONTASAMERAN?

ONTASAMERAN is an innovative medical treatment being studied for patients with advanced melanoma, a serious form of skin cancer[1]. It is part of a combination therapy called BNT111, which includes three other active substances: gindameran, vibosameran, and enomimeran. These substances are collectively known as a mRNA-based cancer immunotherapy.

ONTASAMERAN is specifically designed to target a protein called TPTE, which is found in some melanoma cells[1]. The other components of BNT111 target different proteins associated with melanoma: NY-ESO-1 (gindameran), tyrosinase (vibosameran), and MAGE-A3 (enomimeran).

How does ONTASAMERAN work?

ONTASAMERAN is a type of treatment called mRNA therapy. mRNA stands for messenger RNA, which is a molecule that carries instructions for making proteins in our cells. In this case, ONTASAMERAN contains mRNA that instructs cells to produce the TPTE protein[1].

When ONTASAMERAN is administered to a patient, it helps the body’s immune system recognize and attack melanoma cells that contain the TPTE protein. This approach is designed to stimulate the patient’s own immune system to fight against the cancer more effectively.

Clinical Trial Information

ONTASAMERAN is currently being studied in a clinical trial for patients with advanced melanoma (Stage III or IV) who have not responded well to previous treatments[1]. The trial is testing BNT111 (which includes ONTASAMERAN) in combination with another drug called cemiplimab, as well as testing each treatment separately.

The main goal of this trial is to see how well the combination of BNT111 and cemiplimab works in shrinking tumors or stopping their growth[1]. Researchers will also be looking at how safe the treatments are and how they affect patients’ quality of life.

Potential Benefits

While it’s important to note that ONTASAMERAN is still being studied and its effectiveness is not yet fully known, the researchers hope it may offer several potential benefits for patients with advanced melanoma:

  • Improved response to treatment, especially for patients who haven’t responded well to other therapies
  • Potentially longer survival time
  • A new option for patients with limited treatment choices
  • Possible improvement in quality of life

Eligibility Criteria

The clinical trial has specific criteria for who can participate. Some key points include[1]:

  • Patients must be 18 years or older
  • Have confirmed Stage III or IV melanoma that can’t be surgically removed
  • Have had their cancer worsen despite previous treatment with certain immunotherapy drugs
  • Be in generally good health, with adequate organ function
  • Not have certain other medical conditions that could interfere with the treatment or its evaluation

Safety Considerations

As with any experimental treatment, there are potential risks and side effects to consider. The clinical trial is designed to carefully monitor patients for any adverse reactions<a href="#1". Some general safety considerations include:

  • Possible immune-related side effects, as the treatment stimulates the immune system
  • Regular check-ups and tests to monitor overall health and treatment response
  • Potential interactions with other medications or health conditions

Conclusion

ONTASAMERAN, as part of the BNT111 therapy, represents a promising new approach in the treatment of advanced melanoma. By harnessing the power of mRNA technology and the body’s own immune system, researchers hope to offer new options for patients who have not responded well to existing treatments. As the clinical trial progresses, more information will become available about the effectiveness and safety of this innovative therapy.

Aspect Details
Drug Name BNT111 (containing Ontasameran)
Trial Phase Phase II
Target Condition Advanced Melanoma (Stage III and IV)
Main Objective Assess anti-tumor activity of BNT111 + cemiplimab
Key Eligibility Criteria Age ≥18, unresectable Stage III or IV melanoma, disease progression after anti-PD-1/PD-L1 therapy
Administration Intravenous injection
Maximum Dose 100 μg daily, 3750 μg total
Treatment Duration Up to 104 weeks
Primary Endpoint Objective Response Rate (ORR)
Key Secondary Endpoints Duration of Response, Disease Control Rate, Progression-Free Survival, Overall Survival

FAQ

  • What is Ontasameran and how does it work? Ontasameran is one of four mRNA molecules in the drug BNT111. It specifically encodes for the TPTE protein, which is associated with melanoma. The drug works by stimulating the immune system to recognize and attack cancer cells expressing these proteins.
  • Who is eligible for the clinical trial involving Ontasameran? The trial is for patients aged 18 or older with advanced (Stage III or IV) melanoma that has not responded to previous treatments, including anti-PD-1/PD-L1 therapy. Patients must have adequate organ function and meet specific health criteria.
  • What are the main objectives of the clinical trial? The primary objective is to assess the anti-tumor activity of BNT111 (which includes Ontasameran) in combination with cemiplimab. Secondary objectives include evaluating the effectiveness of each drug alone, assessing overall survival, and monitoring safety and quality of life in patients.
  • How is the drug administered in the trial? BNT111, which contains Ontasameran, is administered through intravenous injection. The maximum daily dose is 100 micrograms, with a maximum total dose of 3750 micrograms over a treatment period of up to 104 weeks.
  • What are the potential side effects or risks of the treatment? While specific side effects are not detailed in the provided information, the trial will closely monitor for treatment-emergent adverse events, including serious or fatal events, and immune-related adverse events. Patients will undergo regular check-ups and laboratory tests to ensure safety.

Ongoing Clinical Trials on Ontasameran

  • Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Poland Spain

Glossary

  • Melanoma: A type of skin cancer that develops in cells called melanocytes, which produce melanin, the pigment that gives skin its color.
  • mRNA: Messenger RNA, a molecule that carries genetic information from DNA to the cell's protein-making machinery.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Immune-related Adverse Events (irAEs): Side effects related to the immune system that can occur with certain cancer treatments.
  • ECOG PS: Eastern Cooperative Oncology Group Performance Status, a scale used to assess how a patient's disease affects their daily living abilities.
  • Unresectable: Unable to be removed completely through surgery.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.

References

  1. http://clinicaltrials.eu/trial/study-of-bnt111-and-cemiplimab-for-patients-with-advanced-melanoma-unresponsive-to-prior-treatments/